抗放射線薬の世界市場：洞察、競合情勢、市場予測：2030年

世界の抗放射線薬の市場規模は、2024年から2030年までの予測期間中に8.79％のCAGRで拡大すると予測されています。抗放射線薬の需要は、主にがん診断処置に伴う副作用の増加、放射線または原子力事故による被曝リスクの急増、核保有大国の放射能防護への傾斜の高まりなどに起因して後押しされており、それによって2024年から2030年までの予測期間中に抗放射線薬市場全体の成長に寄与しています。

FDAによると、コンピュータ断層撮影法（CT）、X線撮影法、従来のマンモグラフィなど、医療用画像診断装置の多くは電離放射線を使用して身体の画像を生成しています。これらの電離放射線はDNAを損傷し、がん発症のリスクを高める可能性が十分にあります。

さらに、国立衛生研究所（NIH）、疾病予防管理センター（CDC）、食品医薬品局（FDA）など、複数の米国政府機関の一部からなる国家毒性プログラム（NTP）は、X線およびガンマ線をヒト発がん性物質に分類しています。

NCI（国立がん研究所）の2019年版によれば、15歳までにCTスキャンを複数回受けた患者は、白血病や脳腫瘍を発症するリスクが高まることが判明しています。さらに、時には高レベルの放射線被曝が組織に影響を及ぼし、脱毛、皮膚の発赤、白内障などを引き起こし、薬剤による抗放射線治療の必要性を悪化させるかもしれません。

したがって、画像診断時の高電離放射線被曝とその副作用による安全性への懸念が、抗放射線医薬品の需要を高めると予想されます。

当レポートでは、世界の抗放射線薬市場について調査し、市場の概要とともに、化合物別、適応症別、放射線タイプ別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 抗放射線薬市場レポートのイントロダクション

第2章 抗放射線薬市場のエグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 抗放射線薬市場の主要な要因分析

• 抗放射線薬市場の促進要因
• 抗放射線薬市場の抑制要因と課題
• 抗放射線薬市場の機会

第6章 抗放射線薬市場におけるポーターのファイブフォース分析

第7章 抗放射線薬市場のレイアウト

• 化合物別
• 適応症別
• 放射線タイプ別
• 流通チャネル別
• 地域別

第8章 抗放射線薬市場の企業と製品プロファイル

• Novartis AG
• Anbex Inc.
• Amgen Inc.
• Myelo Therapeutics
• Arco Pharmaceuticals LLC
• BTG International Inc.
• Cellphire Inc.
• Darnitsa
• Enzychem Lifesciences Corporation
• Humanetics Corporation
• Mission Pharmacal Company
• Chrysalis BioTherapeutics Inc.
• Pluri Inc.
• Partner Therapeutics
• HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG.
• RxBio Inc.
• Coherus Biosciences
• Onconova Therapeutics
• Jubilant Life Sciences
• Soligenix Inc.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Anti-Radiation Drugs Market in Global (2021-2030)
• Table 3: Anti-Radiation Drugs Market in Global by Compound (2021-2030)
• Table 4: Anti-Radiation Drugs Market in Global by Indication (2021-2030)
• Table 5: Anti-Radiation Drugs Market in Global by Radiation Type (2021-2030)
• Table 6: Anti-Radiation Drugs Market in Global by Distribution Channel (2021-2030)
• Table 7: Anti-Radiation Drugs Market in Global by Geography (2021-2030)
• Table 8: Anti-Radiation Drugs Market in North America (2021-2030)
• Table 9: Anti-Radiation Drugs Market in the US (2021-2030)
• Table 10: Anti-Radiation Drugs Market in Canada (2021-2030)
• Table 11: Anti-Radiation Drugs Market in Mexico (2021-2030)
• Table 12: Anti-Radiation Drugs Market in Europe (2021-2030)
• Table 13: Anti-Radiation Drugs Market in France (2021-2030)
• Table 14: Anti-Radiation Drugs Market in Germany (2021-2030)
• Table 15: Anti-Radiation Drugs Market in the United Kingdom (2021-2030)
• Table 16: Anti-Radiation Drugs Market in Italy (2021-2030)
• Table 17: Anti-Radiation Drugs Market in Spain (2021-2030)
• Table 18: Anti-Radiation Drugs Market in the Rest of Europe (2021-2030)
• Table 19: Anti-Radiation Drugs Market in Asia-Pacific (2021-2030)
• Table 20: Anti-Radiation Drugs Market in Asia-Pacific by Country (2021-2030)
• Table 21: Anti-Radiation Drugs Market in China (2021-2030)
• Table 22: Anti-Radiation Drugs Market in Japan (2021-2030)
• Table 23: Anti-Radiation Drugs Market in India (2021-2030)
• Table 24: Anti-Radiation Drugs Market in Australia (2021-2030)
• Table 25: Anti-Radiation Drugs Market in South Korea (2021-2030)
• Table 26: Anti-Radiation Drugs Market in Rest of Asia-Pacific (2021-2030)
• Table 27: Anti-Radiation Drugs Market in the Rest of the World (2021-2030)
• Table 28: Anti-Radiation Drugs Market in the Middle East (2021-2030)
• Table 29: Anti-Radiation Drugs Market in Africa (2021-2030)
• Table 30: Anti-Radiation Drugs Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Anti-Radiation Drugs Market in Global (2021-2030)
• Figure 3: Anti-Radiation Drugs Market in Global by Compound (2021-2030)
• Figure 4: Anti-Radiation Drugs Market in Global by Indication (2021-2030)
• Figure 5: Anti-Radiation Drugs Market in Global by Radiation Type (2021-2030)
• Figure 6: Anti-Radiation Drugs Market in Global by Distribution Channel (2021-2030)
• Figure 7: Anti-Radiation Drugs Market in Global by Geography (2021-2030)
• Figure 8: Anti-Radiation Drugs Market in North America (2021-2030)
• Figure 9: Anti-Radiation Drugs Market in the US (2021-2030)
• Figure 10: Anti-Radiation Drugs Market in Canada (2021-2030)
• Figure 11: Anti-Radiation Drugs Market in Mexico (2021-2030)
• Figure 12: Anti-Radiation Drugs Market in Europe (2021-2030)
• Figure 13: Anti-Radiation Drugs Market in France (2021-2030)
• Figure 14: Anti-Radiation Drugs Market in Germany (2021-2030)
• Figure 15: Anti-Radiation Drugs Market in the United Kingdom (2021-2030)
• Figure 16: Anti-Radiation Drugs Market in Italy (2021-2030)
• Figure 17: Anti-Radiation Drugs Market in Spain (2021-2030)
• Figure 18: Anti-Radiation Drugs Market in the Rest of Europe (2021-2030)
• Figure 19: Anti-Radiation Drugs Market in Asia-Pacific (2021-2030)
• Figure 20: Anti-Radiation Drugs Market in China (2021-2030)
• Figure 21: Anti-Radiation Drugs Market in Japan (2021-2030)
• Figure 22: Anti-Radiation Drugs Market in India (2021-2030)
• Figure 23: Anti-Radiation Drugs Market in Australia (2021-2030)
• Figure 24: Anti-Radiation Drugs Market in South Korea (2021-2030)
• Figure 25: Anti-Radiation Drugs Market in Rest of Asia-Pacific (2021-2030)
• Figure 26: Anti-Radiation Drugs Market in the Rest of the World (2021-2030)
• Figure 27: Anti-Radiation Drugs Market in the Middle East (2021-2030)
• Figure 28: Anti-Radiation Drugs Market in Africa (2021-2030)
• Figure 29: Anti-Radiation Drugs Market in South America (2021-2030)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Marker Opportunities
• Figure 33: PORTER'S Five Force Analysis

Anti-Radiation Drugs Market By Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, And Others), Indication (Acute Radiation Syndrome, Cancer Treatment, And Others), Radiation Type (Ionizing Radiations And Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing increasing number side effects associated cancer diagnostic procedures and surge in risk of exposure to radiological or nuclear accidents around the globe during the forecast period.

The global Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030. The demand for anti-radiation drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.

Anti-Radiation Drugs Market Dynamics:

According to the FDA, most medical imaging equipment such as Computed Tomography (CT), radiography, and conventional mammography all use ionizing radiation to generate images of the body. These ionizing radiations have enough potential to damage DNA and elevate the risk of developing cancer.

In addition, the National Toxicology Program (NTP) formed from parts of several different US government agencies, including the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), has classified x- and gamma radiation as a human carcinogen.

As per the NCI (National Cancer Institute) 2019, patients who have had multiple CT scans before the age of 15 were found to have an increased risk of developing leukemia, and brain tumors. Moreover, sometimes the high levels of radiation exposure can affect tissues and cause hair loss, skin reddening, cataracts, and other problems that might aggravate the need for anti-radiation treatments in the form of drugs.

Therefore, safety concerns due to exposure to high ionizing radiations and their side effects during diagnostic imaging are expected to bolster the demand for anti-radiation pharmaceuticals.

Hence, the interplay of all the above-mentioned factors is anticipated to increase the overall market growth for anti-radiation drugs during the forecast period from 2024 - 2030.

However, the lack of disease-related expertise among healthcare professionals, and ethical and legal complications for finding adequate sample size for clinical trials and research, among others may restrict the growth of the overall market for anti-radiation drugs during the forecast period.

Anti-Radiation Drugs Market Segment Analysis:

Anti-Radiation Drugs Market by Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and others), Indication (Acute Radiation Syndrome, Cancer Treatment, and others), Radiation Type (Ionizing Radiations and Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide.

One form of radioactive material that can be used to help prevent radioactive iodine (I-131) from being absorbed by the thyroid is potassium iodide (KI), a non-radioactive form of iodine. During a nuclear accident, radioactive iodine may be released into the environment in a plume or cloud and subsequently contaminate soil, surfaces, food, and water.

The best results from KI come from taking it immediately before or right after internal radioactive iodine contamination. The amount of radioactive iodine that enters the body and how quickly it is absorbed by the body both affect how effective KI is.

KI is usually presented in scored tablets, which facilitates fractionation for pediatric dosage. The tablets have also been proven as a protective agent during wars for mass protection.

According to the European Commission (2022) in 2022, during the Ukraine war, the Government of Ukraine ordered KI pills from the European Government as a preventative safety measure to increase the level of protection around the Zaporizhzhia nuclear power plant. The potassium iodide tablets would be used in limited scenarios to avoid that inhaled or swallowed radioactive iodine is absorbed by the thyroid; to which the EU Emergency Response Coordination Centre swiftly mobilized 5.5 million potassium iodide tablets via the EU Civil Protection Mechanism for Ukraine.

Therefore, considering the advantages associated with KI in radioactive protection, it is expected to thereby contribute to the overall market growth for anti-radiation drugs during the forecast period from 2024 to 2030.

North America Is Expected To Dominate The Overall Anti-Radiation Drugs Market:

Among all the regions, North America is estimated to account for the largest share of the Anti-Radiation Drugs market in the year 2023. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, rising diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.

For instance, one of the prominent reasons for the requirement for a high number of anti-radiation drugs is the surge in the prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, 2024 data in 2024, it was estimated that approximately 2 million new cancers will be diagnosed in the United States. This ultimately would lead to more demand for anti-radiation drugs resulting from a large number of cancer diagnostic procedures. Moreover, the extensive focus on clinical research and the presence of key players in the region from the pharmaceutical domain further help in the growth of the US anti-radiation drugs treatment market.

Furthermore, in 2022, The US Department of Health and Human Services (HHS) spent USD 290 million on a drug to treat radiation sickness in the event of a nuclear emergency; buying the drug Nplate from Amgen USA Inc. as part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.

Therefore, the interplay of all the above-mentioned factors is expected to aid in the growing demand for anti-radiation drugs, thus driving the overall regional market for North America Anti-Radiation Drugs.

Anti-Radiation Drugs Market Key Players:

Some of the key market players operating in the anti-radiation drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.

Recent Developmental Activities In The Anti-Radiation Drugs Market:

• In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs.
• In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California.
• In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy).

Key Takeaways From The Anti-Radiation Drugs Market Report Study

• Market size analysis for current Anti-Radiation Drugs market size (2023), and market forecast for 6 years (2024-2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Anti-Radiation Drugs market.
• Various opportunities available for the other competitors in the Anti-Radiation Drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Anti-Radiation Drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Anti-Radiation Drugs market growth in the coming future?

Target Audience Who Can Benefit From This Anti-Radiation Drugs Market Report Study

• Anti-Radiation Drugs product providers
• Research organizations and consulting companies
• Anti-Radiation Drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Anti-Radiation Drugs
• Various end-users who want to know more about mental disorders and its related treatment equipment market, along with the latest technological developments in the Anti-Radiation Drugs market.

Frequently Asked Questions For The Anti-Radiation Drugs Market:

1. What is meant by Anti-Radiation Drugs?

Anti-radiation drugs are specially formulated medications that could potentially help limit or treat the health effects of certain types of radiation in a radiological or nuclear emergency.

2. What is the market for global Anti-Radiation Drugs?

The Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Anti-Radiation Drugs market?

The demand for Anti-Radiation Drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.

4. Who are the key players operating in the global Anti-Radiation Drugs market?

Some of the key market players operating in the Anti-Radiation Drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.

5. Which region has the highest share in the Anti-Radiation Drugs market?

North America is expected to dominate the overall Anti-Radiation Drugs market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.

Table of Contents

1. Anti-Radiation Drugs Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Anti-Radiation Drugs Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Anti-Radiation Drugs Market Key Factors Analysis

• 5.1. Anti-Radiation Drugs Market Drivers
  • 5.1.1. Increasing number of side effects associated with cancer diagnostic procedures
  • 5.1.2. Surge in risk of exposure to radiological or nuclear accidents
  • 5.1.3. Rising inclination of nuclear superpower countries towards radioactive protection
• 5.2. Anti-Radiation Drugs Market Restraints and Challenges
  • 5.2.1. Lack of disease-related expertise among healthcare professionals
  • 5.2.2. Ethical and legal complications for finding adequate sample size for clinical trials and research
• 5.3. Anti-Radiation Drugs Market Opportunity
  • 5.3.1. Rising research and development activities in radiopharmaceuticals for the treatment of radiation toxicity

6. Anti-Radiation Drugs Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Anti-Radiation Drugs Market Layout

• 7.1. By Compound
  • 6.1.1 Potassium Iodide
  • 6.1.2 Prussian Blue
  • 6.1.3 Diethylenetriamine Pentaacetic Acid
  • 6.1.4 Colony-stimulating Factors
  • 6.1.5 Others
• 7.2. By Indication
  • 6.2.1 Acute Radiation Syndrome
  • 6.2.2 Cancer Treatment
  • 6.2.3 Others
• 7.3. By Radiation Type
  • 7.3.1. Ionizing Radiations
  • 7.3.2. Non-ionizing Radiations
• 7.4. By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.1.2. Canada Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.1.3. Mexico Anti-Radiation Drugs Market Size in USD million (2021-2030)
  • 7.5.2. Europe Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.2.1. France Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.2.2. Germany Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.2.4. Italy Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.2.5. Spain Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Anti-Radiation Drugs Market Size in USD million (2021-2030)
  • 7.5.3. Asia-Pacific Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.3.1. China Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.3.2. Japan Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.3.3. India Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.3.4. Australia Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.3.5. South Korea Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia-Pacific Anti-Radiation Drugs Market Size in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW) Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.4.1. Middle East Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.4.2. Africa Anti-Radiation Drugs Market Size in USD million (2021-2030)
    • 7.5.4.3. South America Anti-Radiation Drugs Market Size In USD Million (2021-2030)

8. Anti-Radiation Drugs Market Company and Product Profiles

• 8.1. Novartis AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Anbex Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Amgen Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Myelo Therapeutics
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Arco Pharmaceuticals LLC
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. BTG International Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Cellphire Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Darnitsa
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Enzychem Lifesciences Corporation
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Humanetics Corporation
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Mission Pharmacal Company
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Chrysalis BioTherapeutics Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Pluri Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Partner Therapeutics
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. RxBio Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Coherus Biosciences
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Onconova Therapeutics
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Jubilant Life Sciences
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Soligenix Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us